PREVENT 随机对照试验通过生物阻抗谱 (BIS) 与卷尺 (TM) 评估亚临床乳腺癌相关淋巴水肿 (sBCRL) 干预后监测慢性乳腺癌相关淋巴水肿 (cBCRL) 的进展情况。这项多机构试验表明，发生 cBCRL 的风险降低了 92%。这项二次分析回顾了乳腺癌 (BC) 治疗后 sBCRL 和 cBCRL 的时机。使用 BIS 或 TM 定期对有 cBCRL 风险的女性 (n = 919) 进行 BC 治疗后长达 36 个月的筛查。诊断出 sBCRL 后，患者接受了为期 4 周的加压套干预。每 3 个月对从 BC 治疗到检测的时间（以月为单位）进行审查。总共 209 名患者出现 sBCRL（BIS：n = 89，TM：n = 120）并且有资格接受干预。 30 人在干预后进展为 cBCRL（BIS：7，TM：23）。超过一半的患者在 BC 治疗后 9 个月内测量结果与 sBCRL 一致。无论筛查方法如何，患者仍继续进行 sBCRL 初步检测，术后第二年和第三年的检测率保持一致 (p > 0.242)。此外，39 名患者在 3 年期间进展为 cBCRL，但没有发展为 sBCRL 或接受干预。 sBCRL 检测的时机表明，患者在治疗后数年仍处于危险之中，并且可能在手术后数年继续进展为 cBCRL。早期检测 sBCRL 可以进行早期干预，降低进展为 cBCRL 的可能性。完成癌症治疗后，应继续监测患者至少 3 年。具体而言，在最初 9 个月期间进行仔细的有针对性的监测非常重要。© 2024。外科肿瘤学会。

The PREVENT randomized control trial monitored progression to chronic breast cancer-related lymphedema (cBCRL) following intervention for subclinical breast cancer-related lymphedema (sBCRL) assessed by bioimpedance spectroscopy (BIS) versus tape-measure (TM). This multi-institutional trial demonstrated a 92% risk reduction of developing cBCRL. This secondary analysis reviews the timing of sBCRL and cBCRL following breast cancer (BC) treatment.Women at risk of cBCRL (n = 919) were screened regularly up to 36 months after BC treatment using either BIS or TM. Following diagnosis of sBCRL, patients underwent a 4-week compression sleeve intervention. The time in months from BC treatment to detection was reviewed at 3-month intervals.In total 209 patients developed sBCRL (BIS: n = 89, TM: n = 120) and were eligible for intervention. 30 progressed to cBCRL postintervention (BIS: 7, TM: 23). More than half of patients had measurements consistent with sBCRL within 9 months of BC treatment. Patients continued to have initial detections of sBCRL, regardless of screening method, with rates remaining consistent in years two and three (p > 0.242) post surgery. Additionally, 39 patients progressed to cBCRL without developing sBCRL or receiving intervention across the 3-year period.The timing of sBCRL detection demonstrates that patients continue to be at risk years after treatment and may continue to progress to cBCRL years after surgery. Early detection of sBCRL allows for early intervention decreasing the likelihood of progression to cBCRL. Patients should continue to be monitored for a minimum of 3 years following completion of cancer treatment. Specifically, careful targeted monitoring over the initial 9-month period is important.© 2024. Society of Surgical Oncology.